A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

This study tests a drug called APG-2575 in people with mild to moderate systemic lupus erythematosus (SLE) — an autoimmune disease where the immune system mistakenly attacks healthy tissues, causing symptoms like joint pain, rashes, and fatigue. APG-2575 works by blocking a protein that helps certain immune cells survive, potentially reducing the immune activity that causes lupus symptoms. **You may be eligible if...** - You have been diagnosed with lupus for at least 6 months - Your lupus is mild to moderate in severity (SLEDAI score between 4 and 12) - You have been on a stable lupus treatment regimen for at least 28 days before the study - You are otherwise in generally good health **You may NOT be eligible if...** - Your lupus is severe or involves major organs like the kidneys or nervous system - You have another significant autoimmune condition - You have had recent serious infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.